{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:57:29Z","timestamp":1770436649980,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T00:00:00Z","timestamp":1382745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00520-013-2022-1","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T17:13:58Z","timestamp":1382721238000},"page":"679-687","source":"Crossref","is-referenced-by-count":124,"title":["Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors"],"prefix":"10.1007","volume":"22","author":[{"given":"David","family":"Henry","sequence":"first","affiliation":[]},{"given":"Saroj","family":"Vadhan-Raj","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Hirsh","sequence":"additional","affiliation":[]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Penella J","family":"Woll","sequence":"additional","affiliation":[]},{"given":"Giorgio","family":"Scagliotti","sequence":"additional","affiliation":[]},{"given":"Geoffrey","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Amy","family":"Feng","sequence":"additional","affiliation":[]},{"given":"Susie","family":"Jun","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Dansey","sequence":"additional","affiliation":[]},{"given":"Howard","family":"Yeh","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,10,26]]},"reference":[{"key":"2022_CR1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","volume":"97","author":"JE Brown","year":"2005","unstructured":"Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59\u201369","journal-title":"J Natl Cancer Inst"},{"key":"2022_CR2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s\u20136249s","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2022_CR3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2010.10.002","volume":"37","author":"A Lipton","year":"2010","unstructured":"Lipton A (2010) Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 37(Suppl 2):S15\u2013S29","journal-title":"Semin Oncol"},{"key":"2022_CR4","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","volume":"353","author":"RK Portenoy","year":"1999","unstructured":"Portenoy RK, Lesage P (1999) Management of cancer pain. Lancet 353:1695\u20131700","journal-title":"Lancet"},{"key":"2022_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jso.22061","volume":"105","author":"AF Mavrogenis","year":"2012","unstructured":"Mavrogenis AF, Pala E, Romagnoli C, Romantini M, Calabro T, Ruggieri P (2012) Survival analysis of patients with femoral metastases. J Surg Oncol 105:135\u2013141","journal-title":"J Surg Oncol"},{"key":"2022_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162\u2013167","journal-title":"J Urol"},{"key":"2022_CR7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860\u20131867","journal-title":"Cancer"},{"key":"2022_CR8","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621","journal-title":"Cancer"},{"key":"2022_CR9","unstructured":"Zometa\u00ae (Zoledronic acid) Package Insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ. (2009)."},{"key":"2022_CR10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/11207370-000000000-00000","volume":"71","author":"LJ Scott","year":"2011","unstructured":"Scott LJ, Muir VJ (2011) Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Drugs 71:1059\u20131069","journal-title":"Drugs"},{"key":"2022_CR11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"2022_CR12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","volume":"25","author":"WC Dougall","year":"2006","unstructured":"Dougall WC, Chaisson M (2006) The RANK\/RANKL\/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25:541\u2013549","journal-title":"Cancer Metastasis Rev"},{"key":"2022_CR13","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"2022_CR14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"2022_CR15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"2022_CR16","doi-asserted-by":"crossref","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092.","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"2022_CR17","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609\u20132617","journal-title":"Mol Cancer Ther"},{"key":"2022_CR18","doi-asserted-by":"crossref","first-page":"6236s","DOI":"10.1158\/1078-0432.CCR-06-0988","volume":"12","author":"CS Cleeland","year":"2006","unstructured":"Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 12:6236s\u20136242s","journal-title":"Clin Cancer Res"},{"key":"2022_CR19","unstructured":"Chung K, Barlev A, Braun A, Qian Y, Zagari M. Development of the Analgesic Quantification Algorithm (AQA): a new scale to assess changes in analgesic use [abstract no. 3037]. Presented at: ECCO 15 and 34th ESMO Multidisciplinary Congress; Sept 20-24, 2009; Berlin, Germany."},{"key":"2022_CR20","doi-asserted-by":"crossref","unstructured":"Costa L, Fizazi K, Saad F, Brown JE, Von Moos R, Oudard S, Sternberg CN, Ganju V, Miller K, Wang H, Maniar T, Braun A (2013) Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases [abstract no. 5079]. 2013 ACSO Annual Meeting. J Clin Oncol.","DOI":"10.1200\/jco.2013.31.15_suppl.5079"},{"key":"2022_CR21","unstructured":"SERVICES USDOHAH (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Accessed 5 June 2013."},{"key":"2022_CR22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","volume":"17","author":"KP Weinfurt","year":"2006","unstructured":"Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986\u2013989","journal-title":"Ann Oncol"},{"key":"2022_CR23","unstructured":"XGEVA\u00ae (Denosumab) Package Insert. Amgen Inc., Thousand Oaks, CA. (2010)."},{"key":"2022_CR24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744","journal-title":"Cancer"},{"key":"2022_CR25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/annonc\/mdm055","volume":"18","author":"M Kleber","year":"2007","unstructured":"Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M (2007) Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 18:950\u2013958","journal-title":"Ann Oncol"},{"key":"2022_CR26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-008-0131-1","volume":"124","author":"V Launay-Vacher","year":"2010","unstructured":"Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P (2010) Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745\u2013753","journal-title":"Breast Cancer Res Treat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-2022-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-2022-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-2022-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T19:58:07Z","timestamp":1596743887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-2022-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-2022-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,26]]}}}